FTO Enzyme Drives Colorectal Cancer Drug Resistance Through Iron Metabolism Control
A key m6A RNA modifier enables colorectal cancer cells to resist chemotherapy by stabilizing a transcription factor that regulates iron homeostasis.
Summary
Researchers identified FTO, an RNA demethylase that removes m6A modifications from messenger RNA, as a critical driver of chemotherapy resistance in colorectal cancer. Using CRISPR/Cas9 knockout cell lines and conditional knockout mice, the team showed FTO stabilizes NUPR1 mRNA by blocking its degradation at a specific m6A site. NUPR1 then upregulates iron-storage and iron-transport genes (FTH1 and LCN2), preventing iron-mediated cell death (ferroptosis) that chemotherapy would otherwise trigger. Simultaneously blocking both FTO and NUPR1 dramatically improved chemotherapy efficacy in laboratory and animal models, pointing to a promising combination strategy for treatment-resistant colorectal cancer.
Detailed Summary
Colorectal cancer (CRC) is one of the deadliest cancers worldwide, and chemotherapy resistance—particularly to 5-fluorouracil (5-FU) and oxaliplatin—remains the principal obstacle to improving patient survival. Epigenetic RNA modifications, especially N6-methyladenosine (m6A), have emerged as powerful regulators of gene expression in cancer, but which specific m6A enzymes drive chemoresistance in CRC had not been clearly established.
This study began with a bioinformatic analysis of 18 known m6A regulatory genes across TCGA colorectal cancer datasets (638 tumor vs. 51 normal samples). Consensus clustering and survival analysis revealed that m6A gene expression patterns strongly correlate with CRC malignancy stage and patient prognosis. Among all m6A regulators screened, FTO—an m6A eraser enzyme—emerged as the most significantly upregulated gene associated with poor outcomes and chemoresistance.
To dissect the mechanism, the researchers generated FTO knockout CRC cell lines (HT29 and HCT116) using CRISPR/Cas9, as well as intestinal epithelial-specific FTO conditional knockout mice via the Cre/loxP system. RNA sequencing of FTO-knockout cells revealed that loss of FTO markedly downregulated NUPR1, a stress-response transcription factor. Mechanistic experiments showed FTO demethylates a specific m6A site at position +451 of NUPR1 mRNA, preventing the m6A reader protein YTHDF2 from binding and triggering mRNA degradation. When FTO is active, NUPR1 mRNA is stabilized, NUPR1 protein accumulates, and NUPR1 in turn transcriptionally activates LCN2 (lipocalin-2, an iron-transport protein) and FTH1 (ferritin heavy chain 1, an iron-storage protein). This coordinated upregulation sequesters intracellular free iron, suppresses lipid peroxidation, and blocks ferroptosis—the iron-dependent cell death pathway that chemotherapy drugs can engage.
Functional assays confirmed that FTO knockout cells showed elevated intracellular free iron, increased lipid ROS (measured by C11-BODIPY), higher MDA levels, and dramatically greater sensitivity to 5-FU and oxaliplatin both in vitro and in subcutaneous tumor mouse models. Critically, simultaneous knockdown of both FTO and NUPR1 produced additive anti-tumor effects greater than either alone, validating the axis as a therapeutic target. Luciferase reporter assays with wild-type and m6A-mutant NUPR1 sequences confirmed the functional importance of the +451 m6A site.
These findings establish the FTO→NUPR1→LCN2/FTH1 axis as a previously unrecognized mechanism of chemoresistance in CRC, linking epitranscriptomic regulation directly to iron metabolism and ferroptosis susceptibility. The study suggests that pharmacological inhibition of FTO, combined with NUPR1 targeting, could sensitize resistant tumors to standard chemotherapy regimens.
Key Findings
- FTO is the top upregulated m6A regulator in CRC and correlates with poor prognosis and chemoresistance.
- FTO demethylates the +451 m6A site on NUPR1 mRNA, blocking YTHDF2-mediated degradation and stabilizing NUPR1 expression.
- NUPR1 drives iron sequestration via LCN2 and FTH1, suppressing ferroptosis and enabling chemotherapy evasion.
- CRISPR knockout of FTO sensitized CRC tumors to 5-FU and oxaliplatin in both cell lines and mouse models.
- Dual targeting of FTO and NUPR1 produced superior anti-tumor efficacy compared to either target alone.
Methodology
The study combined TCGA bioinformatic analysis of 638 CRC tumors with CRISPR/Cas9 knockout cell lines in HT29 and HCT116 cells and intestinal-specific conditional FTO knockout mice. Mechanistic validation used RNA sequencing, m6A dot blotting, RNA stability assays, luciferase reporter assays, and in vivo subcutaneous tumor models with 5-FU and oxaliplatin treatment.
Study Limitations
All in vivo experiments used subcutaneous xenograft models rather than orthotopic or patient-derived tumor models, which may not fully recapitulate clinical chemoresistance. The study focused on 5-FU and oxaliplatin resistance; whether the FTO-NUPR1 axis extends to other chemotherapy regimens or immunotherapy remains untested. No clinical patient cohort validation of the FTO-NUPR1 protein axis or its association with treatment response was performed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.